AbbVie Reports First-Quarter 2021 Financial Results
The Pharma Data
APRIL 30, 2021
percent on an operational basis, due to biosimilar competition. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab, 150 mg) for the treatment of adults with active psoriatic arthritis (PsA). Humira net revenues were $3.907 billion , an increase of 6.9 Recent Events.
40 
Let's personalize your content